PHP
KROS icon

Parkman Healthcare Partners’s Keros Therapeutics KROS Stock Holding History

Parkman Healthcare Partners’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-217,753
Closed -$2.22M – 94
2025
Q1 		$2.22M Sell
217,753
-96,788
-31% -$1.12M 0.26% 72
2024
Q4 		$4.98M Sell
314,541
-107,241
-25% -$5.57M 0.66% 43
2024
Q3 		$24.5M Buy
421,782
+223,155
+112% +$11M 3.13% 5
2024
Q2 		$9.08M Buy
198,627
+20,292
+11% +$1.09M 1.22% 30
2024
Q1 		$11.8M Sell
178,335
-182,132
-51% -$10.8M 1.45% 24
2023
Q4 		$14.3M Buy
360,467
+61,992
+21% +$1.94M 2.02% 17
2023
Q3 		$9.52M Buy
298,475
+21,660
+8% +$809K 1.74% 14
2023
Q2 		$11.1M Buy
276,815
+97,525
+54% +$4.28M 1.93% 15
2023
Q1 		$7.66M Buy
179,290
+52,500
+41% +$2.65M 1.67% 23
2022
Q4 		$6.09M Buy
126,790
+26,863
+27% +$1.25M 1.62% 19
2022
Q3 		$3.76M Buy
99,927
+52,139
+109% +$1.81M 1.07% 32
2022
Q2 		$1.32M Sell
47,788
-24,902
-34% -$1.09M 0.49% 52
2022
Q1 		$3.95M Buy
72,690
+2,829
+4% +$145K 1.16% 32
2021
Q4 		$4.09M Buy
+69,861
New +$3.48M 0.9% 35

Other funds holding KROS

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Parkman Healthcare Partners's KROS Position: Q2 2025 in Review

Parkman Healthcare Partners sold out of Keros Therapeutics (KROS) in Q2 2025, closing a stake of 217,753 shares — an estimated $2.22M sold.

Parkman Healthcare Partners first reported a position in KROS in Q4 2021 and held it in 14 quarters. The position peaked at $24.5M in Q3 2024. 139 funds tracked by Wall St. Rank hold KROS as of Q2 2025.

  • Parkman Healthcare Partners reported no remaining Keros Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Parkman Healthcare Partners sold 217,753 Keros Therapeutics shares in Q2 2025, an estimated $2.22M.
  • Parkman Healthcare Partners first reported a position in Keros Therapeutics in Q4 2021 and held it in 14 quarters.
  • Parkman Healthcare Partners's Keros Therapeutics position peaked at $24.5M in Q3 2024.
  • 139 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2025.

Based on Parkman Healthcare Partners's 13F filing for Q2 2025, filed 14 Aug 2025.